ATRA

ATRA's headline screen looks irresistible — P/E 4.3, net income +138% to $32.7M, 29.7% operating margin, P/S 0.8 — but every one of those figures is an accounting artifact of a company in retreat, not a profitable operating business. The 10-K is explicit: management is conducting a 'review of strategic alternatives,' carries a going-concern assessment, and warns the board 'may determine to pursue a liquidation and dissolution or other wind down of our business,' in which case cash available to stockholders 'if any' is uncertain. That is the actual investment question here, and it overwhelms the trailing P&L.

The numbers confirm the wind-down. Despite reporting $35.9M of operating income, the company burned -$50.9M in operating cash flow — a ~$87M gap that tells you the 'profit' is non-cash and one-time, consistent with the HCR Molag royalty-monetization and the Pierre Fabre commercialization restructuring described in the filing (Ebvallo/tab-cel is partnered out, not self-commercialized). Meanwhile total assets collapsed -81.5% to $20.2M, R&D was cut -75.3% to $37.4M (a pipeline being shut, not funded), and cash fell -66.1% to just $8.48M. Against a $50.9M annual burn, $8.48M of cash is roughly two months of runway — the definition of needing additional financing or a transaction to survive.